422 related articles for article (PubMed ID: 8194284)
1. The fate of exogenous surfactant in neonates with respiratory distress syndrome.
Hallman M; Merritt TA; Bry K
Clin Pharmacokinet; 1994 Mar; 26(3):215-32. PubMed ID: 8194284
[TBL] [Abstract][Full Text] [Related]
2. Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants.
Hallman M; Merritt TA; Akino T; Bry K
Am Rev Respir Dis; 1991 Dec; 144(6):1376-84. PubMed ID: 1741552
[TBL] [Abstract][Full Text] [Related]
3. Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome: evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure.
Hallman M; Merritt TA; Pohjavuori M; Gluck L
Pediatr Res; 1986 Dec; 20(12):1228-35. PubMed ID: 3797115
[TBL] [Abstract][Full Text] [Related]
4. A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.
Walti H; Monset-Couchard M
Drug Saf; 1998 May; 18(5):321-37. PubMed ID: 9589844
[TBL] [Abstract][Full Text] [Related]
5. Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy.
Rubin BK; Ramirez O; King M
Chest; 1992 Apr; 101(4):1080-5. PubMed ID: 1555424
[TBL] [Abstract][Full Text] [Related]
6. Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review.
Ainsworth SB; Milligan DW
Am J Respir Med; 2002; 1(6):417-33. PubMed ID: 14720029
[TBL] [Abstract][Full Text] [Related]
7. Animal-derived surfactant treatment of respiratory distress syndrome in premature neonates: a review.
Fujii AM; Carillo M
Drugs Today (Barc); 2009 Sep; 45(9):697-709. PubMed ID: 19956811
[TBL] [Abstract][Full Text] [Related]
8. Background to neonatal respiratory distress syndrome and treatment with exogenous surfactant.
Robertson B
Dev Pharmacol Ther; 1989; 13(2-4):159-63. PubMed ID: 2692998
[TBL] [Abstract][Full Text] [Related]
9. Prenatal dexamethasone and exogenous surfactant therapy: surface activity and surfactant components in airway specimens.
Kari MA; Akino T; Hallman M
Pediatr Res; 1995 Nov; 38(5):676-84. PubMed ID: 8552433
[TBL] [Abstract][Full Text] [Related]
10. Surfactant metabolism.
Jobe AH; Ikegami M
Clin Perinatol; 1993 Dec; 20(4):683-96. PubMed ID: 8131362
[TBL] [Abstract][Full Text] [Related]
11. Surfactant replacement in the management of the neonatal respiratory distress syndrome.
Robertson B
Eur J Respir Dis Suppl; 1987; 153():242-8. PubMed ID: 3322864
[TBL] [Abstract][Full Text] [Related]
12. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. The Surfactant-TA Study Group.
Fujiwara T; Konishi M; Chida S; Okuyama K; Ogawa Y; Takeuchi Y; Nishida H; Kito H; Fujimura M; Nakamura H
Pediatrics; 1990 Nov; 86(5):753-64. PubMed ID: 2235230
[TBL] [Abstract][Full Text] [Related]
13. Surfactant use for neonatal lung injury: beyond respiratory distress syndrome.
Finer NN
Paediatr Respir Rev; 2004; 5 Suppl A():S289-97. PubMed ID: 14980286
[TBL] [Abstract][Full Text] [Related]
14. Exogenous surfactant kinetics in infant respiratory distress syndrome: A novel method with stable isotopes.
Torresin M; Zimmermann LJ; Cogo PE; Cavicchioli P; Badon T; Giordano G; Zacchello F; Sauer PJ; Carnielli VP
Am J Respir Crit Care Med; 2000 May; 161(5):1584-9. PubMed ID: 10806159
[TBL] [Abstract][Full Text] [Related]
15. Doppler-derived systolic pulmonary artery pressure in acute neonatal respiratory distress syndrome.
Seppänen MP; Kääpä PO; Kero PO; Saraste M
Pediatrics; 1994 May; 93(5):769-73. PubMed ID: 8165076
[TBL] [Abstract][Full Text] [Related]
16. [The pulmonary surfactant system: physiology, pathologies associated with its alteration and exogenous administration as therapeutic and diagnostic agent].
Calmanovici G; Boccio J; Lysionek A; Salgueiro M; Caro R; Hager A; de Paoli T; Zubillaga M
Acta Physiol Pharmacol Ther Latinoam; 1998; 48(4):175-90. PubMed ID: 9914807
[TBL] [Abstract][Full Text] [Related]
17. Use of surfactant in the prevention and treatment of neonatal respiratory distress syndrome.
Reynolds MS; Wallander KA
Clin Pharm; 1989 Aug; 8(8):559-76. PubMed ID: 2670398
[TBL] [Abstract][Full Text] [Related]
18. Is there a necessity for multiple doses of surfactant for respiratory distress syndrome of premature infants?
Tsakalidis C; Giougki E; Karagianni P; Dokos C; Rallis D; Nikolaidis N
Turk J Pediatr; 2012; 54(4):368-75. PubMed ID: 23692717
[TBL] [Abstract][Full Text] [Related]
19. Lung surfactant phospholipids in the foetus, newborn, and in the adult; evidence of abnormality in respiratory failure.
Hallman M
Ann Chir Gynaecol Suppl; 1982; 196():19-23. PubMed ID: 6961877
[TBL] [Abstract][Full Text] [Related]
20. Surfactant protein A and saturated phosphatidylcholine in respiratory distress syndrome.
Moya FR; Montes HF; Thomas VL; Mouzinho AM; Smith JF; Rosenfeld CR
Am J Respir Crit Care Med; 1994 Dec; 150(6 Pt 1):1672-7. PubMed ID: 7952631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
